Discover
MIRM
Mirum Pharmaceuticals, Inc.
120.46
2 x 84.24
2 x 148.94
bid
ask
+
3.39
2.90%
2 @ 04:00 PM
118.11 -2.35 (1.95%)
| Ytd | 52.50% | |
| 1y | 148.94% |
115.79
day range
120.62
47.89
52 week range
125.39
| Open | 117.93 | Prev Close | 117.07 | Low | 115.79 | High | 120.62 | Mkt Cap | 7.35B |
| Vol | 996.94K | Avg Vol | 992.83K | EPS | -13.60 | P/E | N/A | Forward P/E | -1376.69 |
| Beta | 0.51 | Short Ratio | 9.04 | Inst. Own | 114.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 101.86 | 200-d Avg | 87.81 | 1yr Est | 145.36 |
| Income Statement | |||
| Total Revenue | 159.88M | ||
| Revenues (USD) | 159.88M | ||
| Cost of Revenue | 28.81M | ||
| Gross Profit | 131.08M | ||
| Operating Expenses | 920.54M | ||
| Research and Development Expense | 97.91M | ||
| Selling, General and Administrative Expense | 96.33M | ||
| Operating Income | -789.46M | ||
| Interest Expense | 3.62M | ||
| Income Tax Expense | 475.00K | ||
| Net Income | -790.15M | ||
| Net Income Common Stock | -790.15M | ||
| Net Income Common Stock (USD) | -790.15M | ||
| Consolidated Income | -790.15M | ||
| Earnings per Basic Share | -13.43 | ||
| Earnings per Basic Share (USD) | -13.43 | ||
| Earnings per Diluted Share | -13.43 | ||
| Earning Before Interest & Taxes (EBIT) | -786.06M | ||
| Earning Before Interest & Taxes (USD) | -786.06M | ||
| Weighted Average Shares | 58.85M | ||
| Weighted Average Shares Diluted | 58.85M | ||
| Balance Sheet | |||
| Cash and Equivalents | 326.64M | ||
| Cash and Equivalents (USD) | 326.64M | ||
| Investments | 95.71M | ||
| Investments Current | 61.35M | ||
| Investments Non-Current | 34.35M | ||
| Trade and Non-Trade Receivables | 133.11M | ||
| Current Assets | 569.44M | ||
| Property, Plant & Equipment Net | 15.06M | ||
| Total Assets | 890.92M | ||
| Total Debt | 321.43M | ||
| Current Liabilities | 272.82M | ||
| Debt Non-Current | 321.43M | ||
| Total Liabilities | 648.42M | ||
| Accumulated Retained Earnings (Deficit) | -1.46B | ||
| Accumulated Other Comprehensive Income | -28.00K | ||
| Shareholders Equity | 242.49M | ||
| Shareholders Equity (USD) | 242.49M | ||
| Assets Non-Current | 321.48M | ||
| Total Debt (USD) | 321.43M | ||
| Goodwill and Intangible Assets | 254.15M | ||
| Inventory | 25.52M | ||
| Liabilities Non-Current | 375.60M | ||
| Trade and Non-Trade Payables | 59.40M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 7.42M | ||
| Net Cash Flow from Financing | 270.08M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 28.48M | ||
| Capital Expenditure | -664.00K | ||
| Issuance (Purchase) of Equity Shares | 270.08M | ||
| Net Cash Flow from Investing | -11.57M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -905.00K | ||
| Net Cash Flow from Operations | -228.76M | ||
| Effect of Exchange Rate Changes on Cash | -1.27M | ||
| Share Based Compensation | 36.20M | ||